Netherlands study details ESBL-producing Enterobacteriaceae strategy.
An isolation strategy of contact precautions in multiple-bed rooms was non-inferior to contact precautions in a single-bed room for preventing transmission of ESBL-producing Enterobacteriaceae, a recent study found.
“Non-inferiority of the multiple-bed room strategy might change the current single-bed room preference for isolation of patients with ESBL-producing Enterobacteriaceae and, thus, broaden infection-control options for ESBL-producing Enterobacteriaceae in daily clinical practice,” wrote Marjolein F. Q. Kluytmans-van den Bergh, MD, PhD, with the Department of Infection Control at Amphia Hospital in Breda, Netherlands, in a recent Lancet Infectious Diseasesarticle.
Use of single-bed rooms for control of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae is under debate because the added value when applying contact precautions has not been shown, Kluytmans-van den Bergh wrote.
The researchers conducted a cluster-randomized, crossover, non-inferiority study on medical and surgical wards of 16 Dutch hospitals. During two consecutive study periods, either contact precautions in a single-bed room or contact precautions in a multiple-bed room were applied as the preferred isolation strategy for patients with ESBL-producing Enterobacteriaceae cultured from a routine clinical sample.
Eligible index patients were 18 years or older, had no strict indication for barrier precautions in a single-bed room, had a culture result reported within 7 days of culture and before discharge, and had no wardmate known to be colonized or infected with an ESBL-producing Enterobacteriaceae isolate of the same bacterial species with a similar antibiogram.
A total of 693 index patients and 9,527 wardmates were enrolled in the study and 463 index patients and 7,093 wardmates were included in the per-protocol population.
The primary outcome was transmission of ESBL-producing Enterobacteriaceae to wardmates, which was defined as rectal carriage of an ESBL-producing Enterobacteriaceae isolate that was clonally related to the index patient's isolate in at least one wardmate. The primary analysis was done in the per-protocol population, which included patients who were adherent to the assigned room type.
Then, the 16 hospitals were randomized, eight to each sequence of isolation strategies. All hospitals randomized to the sequence single-bed room then multiple-bed room and five of eight hospitals randomized to the sequence multiple-bed room then single-bed room completed both study periods and were analyzed.
Transmission of ESBL-producing Enterobacteriaceae to at least one wardmate was identified in 4 percent of 275 index patients during the single-bed room strategy period and for 7 percent of 188 index patients during the multiple-bed room strategy period.
The study was funded by the Netherlands Organisation for Health Research and Development.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.